Pericarditis Treatment Market

Pericarditis Treatment Market Snapshot (2022 to 2032)

The worldwide pericarditis treatment market is likely to be worth USD 3.60 Billion in 2022, and is anticipated to grow at a CAGR of 5.24% during the projected period, reaching USD 6 Billion by 2032. The industry is anticipated to grow owing to growing geriatric population. The extensive advancements in the treatment and diagnosis of cardiovascular diseases will drive the pericarditis drugs market to exponential growth.

Furthermore, advancements in the biologics sector will also provide expansive growth prospects between 2022 and 2032.

Report Attribute	Details
Estimated Base Year Value (2021)	USD 3.35 Billion
Expected Market Value (2022)	USD 3.60 Billion
Anticipated Forecast Value (2032)	USD 6 Billion
Projected Growth Rate (2022 to 2032)	5.24% CAGR

Research and development activities are critical to the expansion of the pericarditis drugs market. Because of the increased use of these drugs, the players have focused their efforts on research. The activities aid in the development of new formulations, which significantly increase the growth opportunities in the pericarditis drugs market. All of these factors point to the pericarditis treatment market expanding.

Strategic partnerships are critical in the pericarditis treatment market. The players are engaging in mergers and acquisitions to strengthen their position in the pericarditis treatment market, ultimately sowing the seeds of development.

Pericarditis is a cardiovascular disease characterized by excrescence of the heart's pericardium wall. The chief cause of pericardium disease is pericardium wall inflammation, which is usually caused by a viral infection. Other causes of pericarditis include renal failure, bacterial infections, and the use of certain medications such as procainamide.

Shortness of breath, fatigue, rapid or abnormal heart rhythms, and chest pain are all typical symptoms of pericarditis. Global pericarditis treatment includes both therapeutic and surgical measures. Acute pericarditis can be treated with pain and inflammation medications such as aspirin and ibuprofen. Several antifungal medications are prescribed depending on the cause of the pericarditis disease, and these are projected to generate the most revenue in the pericarditis treatment market.

Anti-inflammatory drugs such as colchicine are prescribed for pericarditis treatment in cases of chronic or recurrent pericarditis. If the patient with pericarditis disease does not respond to anti-inflammatory medications, corticosteroids such as prednisone are prescribed. Aside from medications, other surgical methods of treatment in the pericarditis treatment market are required in patients, especially when all other medical treatments fail.

In addition to that with multiple medication options for disease treatment available, the pericarditis treatment market may see new opportunities. The introduction of biologics, the adoption of dual therapy, the greater prevalence of idiopathic pericarditis, and product approvals are driving the anticipated growth of the pericarditis treatment market.

Which are Some Prominent Drivers Spearheading Pericarditis Treatment Market Growth?

The rising prevalence of cardiovascular diseases around the world is a major growth driver for the Global Pericarditis Treatment Market. The growing geriatric population has also been influencing the pericarditis treatment market. Acute pericarditis is the most common disease in several clinical settings, according to Cureus, an open access medical journal for a new generation of doctors and patients.

Acute pericarditis has been reported to affect between 0.1 and 0.2% of hospitalized patients, with 5% of patients admitted to the emergency department with non-ischemic chest pain. Furthermore, cardiovascular diseases kill 17.9 million people worldwide each year, accounting for an estimated 31% of all deaths. Low- and middle-income countries account for more than 75% of cardiovascular deaths. The use of dual therapy to treat idiopathic pericarditis is a major factor driving the global pericarditis treatment market. Aspirin is traditionally used as a monotherapy to treat acute pericarditis.

Furthermore, increased smoking, alcohol consumption, and lifestyle changes are major contributors to the rise in cardiovascular diseases, as well as the pericarditis treatment market. More emphasis on the prevention and treatment of cardiovascular diseases in low- and middle-income countries is expected to drive the growth of the Pericarditis treatment market.

What are the Challenges Faced by the Pericarditis Treatment Industry?

As a result of the increased prevalence of idiopathic pericarditis with repeated episodes, the use of dual therapy, such as aspirin with colchicine, is expected to rise. Aspirin is traditionally used as a monotherapy to treat acute pericarditis. However, clinical trials for dual therapy with the combination of two drugs - aspirin and colchicine - for the treatment of pericarditis are underway. When compared to conventional monotherapy, the results show that combination therapy is more effective in reducing pericarditis recurrence.

As a result of the increased prevalence of idiopathic pericarditis with repeated episodes, the use of dual therapy, such as aspirin with colchicine, is expected to rise. However, the presence of misbranded drugs, surgical intervention, and stringent government rules and regulations are expected to impede the growth of the global pericarditis drugs market in the upcoming years. Moreover, rising healthcare costs are also expected to drive the global pericarditis treatment market.

Why is Asia-Pacific emerging as an Opportunistic Pericarditis Treatment Market?

Because of its large population and high prevalence of cardiovascular diseases, Asia Pacific is expected to have a significant revenue share in the global pericarditis treatment market.

The Asia Pacific pericarditis treatment market is anticipated to expand rapidly during the forecast period, owing to an increase in the number of cardiac surgeries, an uptick in patients with cardiovascular disorders, and broadening health care infrastructure.

How is North America Contributing to Growth of the Pericarditis Treatment Market?

According to Future Market Insights, owing to its large network of medical and high-quality healthcare infrastructure, North America is expected to hold the largest share of the Pericarditis Treatment Market. Because North America has a large number of clinical research laboratories, it is anticipated to spur pericarditis treatment market.

Furthermore, this is due to the increasing amount of people diagnosed with cardiac disorders, as well as significant R&D and health-care spending. Furthermore, increased awareness of cardiovascular disorders is expected to drive market growth in North America.

Market Competition

Some of the key participants present in the global Pericarditis Treatment market include Pfizer Inc., Bayer AG, PerkinElmer Inc., ALLERGAN, Lincoln Pharmaceuticals Ltd., Unicure India Pvt. Ltd., Zydus Cadila Healthcare Ltd., Twilight Mercantiles Pvt. Ltd., Aasraw Biochemical Technology Co.ltd, Sun Pharmaceutical Industries Ltd. among others.

As a result of the presence of a larger number of international and local players, the worldwide pericarditis drugs market is moderately competitive.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 5.24% from 2022 to 2032
Market Value for 2022	USD 3.6 Billion
Market Value for 2032	USD 6 Billion
Base Year for Estimation	2021
Historical Data	2017 to 2021
Forecast Period	2022 to 2032
Quantitative Units	Revenue in USD Million and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Disease Type, Treatment, End User, Region
Regions Covered	North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East and Africa
Key Countries Profiled	USA, Canada, Mexico, Brazil, Germany, Italy, France, UK, Spain, BENELUX, Russia, China, Japan, South Korea, India, ASEAN, Australia & New Zealand, GCC, Turkey, South Africa
Key Companies Profiled	Pfizer Inc.; Bayer AG; PerkinElmer Inc.; ALLERGAN; Lincoln Pharmaceuticals Ltd.; Unicure India Pvt. Ltd.; Zydus Cadila Healthcare Ltd.; Aasraw Biochemical Technology Co. Ltd.; Sun Pharmaceutical Industries Ltd.
Customization	Available Upon Request

Key Segments Profiled in the Pericarditis Treatment Industry Survey

Pericarditis Treatment Market by Disease Type:

• Acute Pericarditis Treatment
• Chronic Pericarditis Treatment
• Recurrent Pericarditis Treatment
• Idiopathic Pericarditis Treatment

Pericarditis Treatment Market by Treatment Type:

• Pericarditis Therapeutics
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Antibiotic/Antifungal Medication
• Corticosteroids
• Pericarditis Treatment through Surgery
• Pericardiectomy
• Pericardiocentesis
• Pericardiotomy

Pericarditis Treatment Market by End Use:

• Pericarditis Treatment in Hospitals
• Pericarditis Treatment in Clinics
• Pericarditis Treatment in Ambulatory Surgical Centers
• Pericarditis Treatment in Academic & Research Institutes

Pericarditis Treatment Market by Region:

• North America Pericarditis Treatment Market
• Latin America Pericarditis Treatment Market
• Europe Pericarditis Treatment Market
• East Asia Pericarditis Treatment Market
• South Asia and Pacific Pericarditis Treatment Market
• Middle East & Africa Pericarditis Treatment Market

Frequently Asked Questions

What is the anticipated growth of the pericarditis treatment market until 2032?

FMI projects the global Pericarditis Treatment market to expand at a 5.24% value CAGR by 2032

Which region is forecast to be the most lucrative for Pericarditis Treatment market growth?

Asia Pacific is expected to be the most opportunistic Pericarditis Treatment market, expanding at a 5% CAGR during the forecast period.

Which are some prominent pericarditis treatment providers?

Pfizer Inc., Bayer AG, PerkinElmer Inc., ALLERGAN, Lincoln Pharmaceuticals Ltd., Unicure India Pvt. Ltd., Zydus Cadila Healthcare Ltd. and Twilight Mercantiles Pvt. Ltd., are some prominent pericarditis treatment manufacturers